400 Farmington Avenue, MC6409
Farmington, CT 06032
Nicole Wagner, President and CEO – Nicole.Wagner@lambdavision.com
LambdaVision Incorporated (LVI) is developing a high resolution protein-based retinal implant to restore vision to the millions of patients suffering from retinal degenerative diseases, particularly retinitis pigmentosa (RP) and age-related macular degeneration (AMD). This patent protected technology utilizes the light-activated protein, bacteriorhodopsin, to replace the function of the photoreceptor cells. The flexible, subretinal implant is powered by incident light and does not require any external power supplies or bulky hardware on or outside the eye, and offers the potential for far greater resolution than competing electrode-based technologies.